Prime Medicine PM577a Wilson disease prime-editing trial

Mapped to your portfolio

Overview

Description Prime Medicine has moved PM577a into a global Phase 1/2 human trial for H1069Q-mutated Wilson disease using in vivo Prime Editing. Overview Prime Medicine began a global Phase 1/2 clinical trial of PM577a by dosing the first patient with H1069Q-mutated Wilson disease. The company described the milestone as the first…

Possible scenarios

42%Early Clinical Success+0.0%
28%Slow Dose Escalation0.0%
20%Safety Or Efficacy Setback-0.0%

For information only. Not investment advice.

Stories in this saga

1 story, 1 source

Oct 5, 2026
Prime Medicine Doses First Patient in First in vivo Prime Editing Trial

Prime Medicine PM577a Wilson disease prime-editing trial

Mapped to your portfolio

Overview

Possible scenarios

Stories in this saga

Prime Medicine Doses First Patient in First in vivo Prime Editing Trial

Portfolio

Portfolio

Possible scenarios

Mapped to your portfolio

Mapped to your portfolio

Overview

Possible scenarios

Keeping an eye on this saga?

Stories in this saga

Prime Medicine Doses First Patient in First in vivo Prime Editing Trial

Portfolio

Portfolio

Possible scenarios

Mapped to your portfolio